Clinical trial
Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.
NCT03102242 is registered in ClinicalTrials.gov with Alliance Foundation Trials, LLC. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 1, 2017
- Completion date
- October 1, 2022
- Enrollment
- 64 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.